IMPRIMIS PHARMACEUTICALS INC's ticker is IMMY and the CUSIP is 45323A201. A total of 42 filers reported holding IMPRIMIS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,715,000 | – | 301,415 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,722,000 | $9,798,000 | 3.66% |
| Diametric Capital, LP | 252,160 | $1,453,000 | 1.12% |
| Birchview Capital, LP | 180,000 | $1,024,000 | 0.97% |
| EAM Global Investors LLC | 206,445 | $1,175,000 | 0.64% |
| EAM Investors, LLC | 301,415 | $1,715,000 | 0.47% |
| BARD ASSOCIATES INC | 51,550 | $293,000 | 0.17% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 85,569 | $487,000 | 0.11% |
| ARDSLEY ADVISORY PARTNERS LP | 75,000 | $427,000 | 0.11% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 112,859 | $642,000 | 0.04% |
| ELLINGTON MANAGEMENT GROUP LLC | 16,500 | $94,000 | 0.03% |